Treatment with elexacaftor-tezacaftor-ivacaftor is associated with reduced levels of systemic inflammatory markers, which correlate with improved lung function in patients with cystic fibrosis.

Dr. Drucy Borowitz helped turn cystic fibrosis from a deadly childhood illness into a treatable condition, giving families ...

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.

Arcturus Therapeutics (($ARCT)) announced an update on their ongoing clinical study. Study Overview: Arcturus Therapeutics is conducting a Phase 2 ...

In a historic development for cystic fibrosis (CF) patients worldwide, Beximco Pharmaceuticals Ltd has introduced Triko, a low-cost generic version of Trikafta, the breakthrough triple combination ...

On2, 2025, Arcturus Therapeutics Holdings announced interim Phase 2 clinical results for ARCT-032, its investigational inhaled mRNA therapy for cystic fibrosis, sharing details on mucus reduction and ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

Non-profit patient advocacy groups, patient groups and others in various parts of the world have come together to launch a community-run buyers' club to access a new generic version of a lifesaving ...

Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...

I’m glad that my story was shared during the first plenary at the North American Cystic Fibrosis Conference that focused on the effects of modulators on people with CF.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the ...